在LVAD候选人中预测右心力衰竭:当前的方法和未来的方向
Frederick Vogel1, Zachary W Sollie2, Arman Kilic2
1Department of Bioengineering, College of Engineering, Computing and Applied Sciences, Clemson University, Clemson, SC 29634, USA.
Journal of cardiovascular development and disease
|July 25, 2025
概括
右心力衰竭 (RHF) 通常发生在左心室辅助装置 (LVAD) 植入后. 确定术前指标对于预测RHF和指导治疗决策至关重要.
科学领域:
- 心脏病学 心脏病学
- 医疗器械 医疗器械
- 心脏衰竭研究研究
背景情况:
- 右心力衰竭 (RHF) 是左心室辅助器件 (LVAD) 植入后的一个显著并发症.
- 接受LVAD植入的患者有先前存在的疾病,使他们易患RHF.
- 鉴于LVAD在各种治疗策略中的作用,准确预测RHF至关重要.
研究的目的:
- 审查目前对LVAD后RHF的预测模型.
- 确定关键的临床,实验室,血液动力学和心声回声学指标.
- 探索新的方法来提高RHF预测准确度.
主要方法:
- 对LVAD后RHF预测现有文献的系统审查.
- 分析当前预测模型中使用的各种参数.
- 评估新兴技术,如机械学和机器学习方法.
主要成果:
- 对于LVAD后的RHF现有预测模型的准确性因RHF定义的不同而有所不同.
- 肺动脉脉动指数 (PAPi) 和右心室纵向应变显示出增强当前模型的前景.
- 机械学和机器学习方法为RHF预测提供了一个范式转变.
结论:
- 准确预测LVAD后的RHF仍然是一个挑战.
- 完善RHF定义并纳入新的参数,如PAPI和RV菌株,可以改善预测.
- 先进的计算方法对未来的RHF风险评估具有重大潜力.
相关概念视频
Cardiomyopathy V: Interprofessional Care
34
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
34
Heart Failure VI: Adjunct Therapies
28
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
28
Heart Failure V: Medical Management
25
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
25
Heart Failure II: Pathophysiology
44
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
44
Heart Failure IV: Classification and Diagnostic Evaluation
33
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
33
Cardiomyopathy II: Dilated Cardiomyopathy
23
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
23


